Can venlafaxine in breast milk attenuate the norepinephrine and serotonin reuptake neonatal withdrawal syndrome

J Obstet Gynaecol Can. 2006 Apr;28(4):299-301. doi: 10.1016/S1701-2163(16)32135-1.

Abstract

A newborn infant whose mother had used venlafaxine, a selective inhibitor of both norepinephrine and serotonin reuptake, throughout pregnancy exhibited signs consistent with the norepinephrine and serotonin reuptake withdrawal syndrome. Is it possible that mother's milk can help mitigate the effects of norepinephrine and serotonin reuptake withdrawal? Pharmacokinetic analysis and review of the only published case with active treatment of a baby with venlafaxine suggest that breastfeeding may mitigate the neonatal withdrawal syndrome.

Publication types

  • Case Reports
  • Clinical Conference

MeSH terms

  • Breast Feeding*
  • Cyclohexanols / administration & dosage
  • Cyclohexanols / adverse effects*
  • Diagnosis, Differential
  • Female
  • Humans
  • Infant, Newborn
  • Neonatal Abstinence Syndrome / diagnosis*
  • Neonatal Abstinence Syndrome / etiology
  • Neonatal Abstinence Syndrome / pathology
  • Neonatal Abstinence Syndrome / therapy
  • Pregnancy
  • Serotonin Uptake Inhibitors / administration & dosage
  • Serotonin Uptake Inhibitors / adverse effects*
  • Venlafaxine Hydrochloride

Substances

  • Cyclohexanols
  • Serotonin Uptake Inhibitors
  • Venlafaxine Hydrochloride